PREOPANC SERIOUS ADVERSE EVENT FORM Septform 10

First Page		Document Content
Date: 2014-10-14 11:19:39 Organic chemistry Concomitant drug Pharmacy Fax Gemcitabine Methadone Eli Lilly and Company Chemistry Technology		PREOPANC SERIOUS ADVERSE EVENT FORM Septform 10 Add to Reading List Source URL: www.pancreaskanker.nl Download Document from Source Website File Size: 140,41 KB Share Document on Facebook

	1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Gemzar safely and effectively. See full prescribing information for Gemzar. GEMZAR (gemcitabine for injection), fo DocID: 1u0Nb - View Document
	Final Results of a Phase 1b of Tarextumab (OMP-59R5) (anti-Notch2/3 antibody) in Combination with Nab-paclitaxel and Gemcitabine (Nab P+Gem) in Patients (pts) with Untreated Metastatic Pancreatic Cancer (mPC): ALPINE Stu DocID: 1t7ew - View Document
	Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Colin Weekes,1 DocID: 1t6TW - View Document
	Preclinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer Manuel Hidalgo, Antonio Cubillo, Robert Stagg, Jakob Dupont, Wan-Ching Yen**, Tim DocID: 1t3Wy - View Document
	A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years) DocID: 1sZz9 - View Document